MESOBLAST LTD ADR (MESO) is up +16.06% in the latest session. Our newswire has captured 1 story on MESO across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100).
MESO stock surged 9.14% to $17.02 on August 18, 2026, driven by the completion of patient treatment in its Phase 3 clinical trial for chronic low back pain. The trial, known as MSB-DR004, involves the allogeneic cell therapy rexlemestrocel-L and is a key milestone for the company. Investors are reacting positively to the progress, despite the fact that results are not expected until mid-2027.
Mesoblast Limited announced that it has completed patient treatment in its Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain. This trial enrolled 350 patients and represents a pivotal step in the company's development pipeline. The completion of this phase is a major milestone for Mesoblast, which is a global leader in allogeneic cellular medicines for inflammatory diseases. The company has positioned this treatment to target a $10 billion market for regenerative back pain therapies. The news was reported by multiple sources, including InvestorsHub, The Fly, and Business Insider, all highlighting the significance of the trial's progress.
Despite the positive stock move, Mesoblast remains unprofitable, with a trailing twelve-month (TTM) earnings per share of -0.07 and a net margin of -144.3%. However, the company's revenue has grown significantly, rising 1,053.2% TTM. The stock has traded between $12.66 and $21.50 over the past 52 weeks. On August 18, it printed seven fresh 52-week lows, indicating a recent period of weakness before the rally. The stock's beta of 0.81 suggests it is less volatile than the broader market. The recent completion of the Phase 3 trial may signal a shift in investor sentiment.
The next key event for Mesoblast will be the release of Phase 3 trial results in mid-2027. Investors will be closely watching how the data is received by the market and whether it leads to regulatory submissions or partnerships. Coverage breadth is also a factor to monitor as the story continues to develop.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter...
MESOBLAST LTD ADR (MESO) is up +16.06% in the latest session. Our newswire has captured 1 story on MESO across 1 source in the last 36 hours, with AI sentiment reading mixed (avg 50/100). The most recent driver: "Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)" (Business Insider).
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of MESO coverage reads 50/100 over 1 stories; treat it as a research signal and do your own diligence.
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More on MESO: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier MESO move explainers: 2026-08-18 · 2026-08-17